Diagnostic accuracy of multi-parametric MRI and transrectal ultrasound-guided biopsy in prostate cancer
Recent randomised controlled trials of prostate cancer screening and treatment have reported disappointing results. PLCO 1 failed to demonstrate a benefi t for population-based prostate-specifi c antigen (PSA) screening, while ERSPC 2 reported a survival benefi t, but 781 men needed to be invited for screening and 27 diagnosed with cancer to prevent one death. Furthermore, the PIVOT 3 (2012) and ProtecT 4 (2016) studies investigated treatment versus observation for localised PSA-detected prostate cancer and reported no mortality benefi t for treatment over observation.
Novel diagnostic tests with higher discriminative abilities for aggressive prostate cancer are therefore urgently needed. Multi-parametric MRI might be used as a second-line diagnostic tool in men with abnormal PSA or digital rectal examination to improve selection for biopsy.
In The Lancet, Hashim U Ahmed and colleagues report the PROMIS study, 5 which aimed to determine the accuracy of multi-parametric MRI for detecting intermediate-risk and high-risk prostate cancer, using a highly robust reference test: 5mm grid-template transperineal biopsy with 60-70 cores (TTMB) + 12-core transrectal ultrasound-guided biopsy (TRUSB). They reported a high sensitivity (93%) and moderate specifi city (41%). The study design and results are similar to our study 6 of 388 men in which we performed 30-core TTMB as the reference test and reported sensitivity of 96%, specifi city of 36%, negative predictive value of 92% and positive predictive value of 52% for MRI.
Although the primary objective of PROMIS was to determine the accuracy of MRI, on secondary endpoint analysis, MRI was compared to TRUSB (using TTMB as the reference test) and was more sensitive (93% vs 48%, p<0·001). Although the sensitivity of TRUSB might have been compromised by performing it after TTMB, these results are consistent with those of Pokorny and colleagues 7 who compared sensitivity of in-gantry MRI-biopsy (92%) to TRUSB (70%) and Siddiqui and colleagues 8 who compared MRI-US fusion biopsy (77% sensitivity) to TRUSB (53%). Due to the methodological limitations of performing targeted biopsy or TTMB and TRUSB in the same patient, several randomised controlled trials are now underway that compare MRI-targeted biopsy against TRUSB.
This study adds considerable weight to the literature because of its large sample size (thereby increasing precision of accuracy estimates), the multi-centre design with variable prostate MRI expertise (which increases the generalisability of the fi ndings), use of advanced cancer defi ned by grade and volume as the endpoint (increasing the clinical utility of accuracy estimates), and-perhaps most importantly-use of a highly reliable reference test. Although too invasive for routine clinical use, TTMB + TRUSB provides a near ideal reference test given that radical prostatectomy cannot ethically be performed in men without signifi cant cancer fi ndings on biopsy.
The high sensitivities reported in both PROMIS 9 and our study 6 (the two largest studies to date, with 576 and 388 men respectively) suggests that the lower estimates in previous meta-analyses 9 ,10 might be infl uenced by confounding factors such as small sample size, use of radical prostatectomy as the reference test, and use of any cancer as the endpoint defi nition. Ahmed and colleagues demonstrate that MRI could reduce biopsies, and overdetection and underestimation of high-risk tumours (eg, anterior tumours missed by TRUSB).
The recently reported ProtecT multi-centre trial 4 provides further impetus for a change to more selective biopsy: at 10-years median follow-up in 1643 men, prostate cancer-specifi c mortality was very low (1%) with no diff erence between surveillance, surgery, and radiation arms, suggesting high overdetection and overtreatment rates. Conversely, 21% of men with low risk disease who underwent surveillance experienced progression (local symptoms or metastases), implying that harm was caused by undertreatment.
The ProtecT results will therefore further fuel criticisms that PSA screening and TRUSB perform poorly for selectively detecting aggressive tumours that require radical treatment and for risk-stratifying men. In our view the solution is not to abandon prostate cancer screening altogether, but rather to improve it by adding the anatomic and functional information provided by MRI and the biologic information provided by genetic tools such as Stockholm-3, 11 Oncotype Dx, 12 Decipher, 13 and others into predictive nomograms that guide selection for biopsy and active surveillance. This approach might reduce overdetection, overtreatment and undertreatment, thus improving oncologic, quality of life, and cost-effi ciency outcomes for the population. Future research should be devoted to developing such models and assessing their utility in terms of decision making and cost-benefi t.
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